Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

ABSTRACT: The discovery of robust antidepressant effects of ketamine in refractory patients has led to increasing focus on agents targeting glutamatergic signaling as potential novel antidepressant strategy. Among the agents targeting the glutamatergic system, compounds acting at metabotropic glutamate (mGlu) receptors are among the most promising agents under studies for depressive disorders. Further, the receptor diversity, distinct distribution in the CNS, and ability to modulate the glutamatergic neurotransmission in the brain areas implicated in mood disorders make them an exciting target for stress-related disorders. In preclinical models, antidepressant and anxiolytic effects of mGlu₅ negative allosteric modulators (NAMs) have been reported. Interestingly, mGlu_2/3 recept

SUBMITTER: Dogra S 

PROVIDER: S-EPMC8435015 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature